Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)

• Status: Completed
• Trial end date: 2002-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Cetirizine; Montelukast

Criteria

Inclusion Criteria:

• Patient has a documented clinical history of perennial allergic rhinitis

• Patient is a nonsmoker

• Patient is in good general health

Exclusion Criteria:

• Patient is hospitalized

• Patient is a woman who is <8 weeks postpartum or is breast-feeding

• Patient is a current or past abuser of alcohol or illicit drugs